These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 5985262)

  • 1. In vitro activity of lysostaphin.
    Quinn EL; Jones DN; Steinhauer BW; Cox F
    Antimicrob Agents Chemother (Bethesda); 1966; 6():382-8. PubMed ID: 5985262
    [No Abstract]   [Full Text] [Related]  

  • 2. Lysostaphin-coated catheters eradicate Staphylococccus aureus challenge and block surface colonization.
    Shah A; Mond J; Walsh S
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2704-7. PubMed ID: 15215130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Staphylococcal spheroplasts and L colonies. IV. Antimicrobial susceptibility of stable methicillin-induced and lysostaphin-induced spheroplasts.
    Watanakunakorn C; Goldberg LM; Carleton J; Hamburger M
    Antimicrob Agents Chemother (Bethesda); 1968; 8():382-7. PubMed ID: 5195739
    [No Abstract]   [Full Text] [Related]  

  • 4. Susceptibility of Staphylococcus epidermidis to lysostaphin and major antimicrobial agents.
    Pulverer G; Jeliaszewicz J
    Chemotherapy; 1973; 19(2):109-14. PubMed ID: 4762803
    [No Abstract]   [Full Text] [Related]  

  • 5. In vitro activity of lysostaphin, mupirocin, and tea tree oil against clinical methicillin-resistant Staphylococcus aureus.
    LaPlante KL
    Diagn Microbiol Infect Dis; 2007 Apr; 57(4):413-8. PubMed ID: 17141452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro effect of lysostaphin, neomycin, and bacitracin on Staphylococcus aureus.
    Zygmunt WA; Browder HP; Tavormina PA
    Can J Microbiol; 1966 Feb; 12(1):204-6. PubMed ID: 5923134
    [No Abstract]   [Full Text] [Related]  

  • 7. Staphylococcal strains with relation to lysostaphin sensistivity.
    Schindler CA
    Nature; 1966 Mar; 209(5030):1368-9. PubMed ID: 5956066
    [No Abstract]   [Full Text] [Related]  

  • 8. Lysostaphin: an enzymatic approach to staphylococcal disease. I. In vitro studies.
    Schaffner W; Melly MA; Hash JH; Koenig MG
    Yale J Biol Med; 1967 Feb; 39(4):215-29. PubMed ID: 5182857
    [No Abstract]   [Full Text] [Related]  

  • 9. The phage K lytic enzyme LysK and lysostaphin act synergistically to kill MRSA.
    Becker SC; Foster-Frey J; Donovan DM
    FEMS Microbiol Lett; 2008 Oct; 287(2):185-91. PubMed ID: 18721148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A modified assay of neutrophil function: use of lysostaphin to differentiate defective phagocytosis from impaired intracellular killing.
    Tan JS; Watanakunakorn C; Phair JP
    J Lab Clin Med; 1971 Aug; 78(2):316-22. PubMed ID: 5567568
    [No Abstract]   [Full Text] [Related]  

  • 11. Lysostaphin: an antistaphylococcal agent.
    Kumar JK
    Appl Microbiol Biotechnol; 2008 Sep; 80(4):555-61. PubMed ID: 18607587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of Lif, the lysostaphin immunity factor, on acceptors of surface proteins and cell wall sorting efficiency in Staphylococcus carnosus.
    Strauss A; Thumm G; Götz F
    J Bacteriol; 1998 Sep; 180(18):4960-2. PubMed ID: 9733703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent, synergistic inhibition of Staphylococcus aureus upon exposure to a combination of the endopeptidase lysostaphin and the cationic peptide ranalexin.
    Graham S; Coote PJ
    J Antimicrob Chemother; 2007 Apr; 59(4):759-62. PubMed ID: 17324959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Differentiation between Staphylococcus and Micrococcus genera in the routine laboratory diagnosis using the lysostaphin sensitivity test].
    Witte W; Reissbrodt R; Dünnhaupt K; Ziesché K
    Z Gesamte Hyg; 1986 Jun; 32(6):389-90. PubMed ID: 3529658
    [No Abstract]   [Full Text] [Related]  

  • 15. Nuclease production and lysostaphin susceptibility of Staphylococcus aureus and other catalase-positive cocci.
    Lachica RV; Hoeprich PD; Genigeorgis C
    Appl Microbiol; 1971 May; 21(5):823-6. PubMed ID: 5574317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Staphylococcal spheroplasts and L-colonies. 3. Induction by lysostaphin.
    Watanakunakorn C; Goldberg LM; Carleton J; Hamburger M
    J Infect Dis; 1969 Jan; 119(1):67-74. PubMed ID: 5765044
    [No Abstract]   [Full Text] [Related]  

  • 17. Classification and lysostaphin susceptibility of airborne staphylococci.
    Terayama K; Hirata F; Ohno H; Kawarabayashi T
    Hokkaido Igaku Zasshi; 1983 May; 58(3):313-6. PubMed ID: 6618426
    [No Abstract]   [Full Text] [Related]  

  • 18. Osmotic fragility and viability of lysostaphin-induced staphylococcal spheroplasts.
    Schuhardt VT; Klesius PH
    J Bacteriol; 1968 Sep; 96(3):734-7. PubMed ID: 5732506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Sensitivity to lysostaphin lysis of staphylococci isolated from ovine mastitic milk].
    Gutiérrez L; Garciá ML; Moreno B
    Microbiol Esp; 1981; 34():17-28. PubMed ID: 7200189
    [No Abstract]   [Full Text] [Related]  

  • 20. Antibiotic activity against intraleukocytic Staphylococcus aureus in vitro and in experimental mastitis in mice.
    Craven N; Anderson JC
    Am J Vet Res; 1983 Apr; 44(4):709-12. PubMed ID: 6553464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.